Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F-652 + systemic corticosteroids
- Development stage
- Unknown
- Lead developer
- Evive Biotech
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
F-652 + systemic corticosteroids is a combination therapy consisting of F-652—a recombinant fusion protein dimer of human interleukin-22 (IL-22) and immunoglobulin G2 Fc fragment—with systemic corticosteroids (such as methylprednisolone or prednisone) used for immunosuppression. F-652 acts as an **interleukin-22 receptor agonist**, promoting epithelial regeneration, suppressing inflammation, and upregulating antimicrobial molecules. The combination with corticosteroids aims to augment mucosal healing in diseases characterized by immune-mediated epithelial damage, notably **acute lower gastrointestinal graft-versus-host disease (GI GVHD)**. Clinical data demonstrate that this combination is safe, with a 70% day-28 response rate in a phase 2 trial for newly diagnosed lower GI acute GVHD, and is associated with improved mucosal recovery and gut microbial diversity.
- Other names
- recombinant human interleukin-22 IgG2-Fc dimer + systemic corticosteroids
02
Targets
GR (Glucocorticoid receptor)IL-22R (Interleukin 22 Receptor)
Beyond the preview
Go deeper on F-652 + systemic corticosteroids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F-652 + systemic corticosteroids.